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Abstract
According to the World Health Organization, metabolic syndrome (MetS) can be defined as a pathological condition characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. The incidence of MetS
keeps rising, as at least 35% of the USA population suffers from MetS. One of the worst comorbidities of metabolic
syndrome are cardiovascular diseases that significantly amplifies the mortality associated with this syndrome. There is
an urgent need to understand the pathophysiology of MetS to find novel diagnosis, treatment and management to
mitigate the MetS and associated complications. Altered circulatory adiponectin levels have been implicated in MetS.
Adiponectin has numerous biologic functions including antioxidative, anti-nitrative, anti-inflammatory, and cardioprotective effects. Being a pleiotropic hormone of multiple tissues, tissue-specific key signaling pathways of adiponectin
will help finding specific target/s to blunt the pathophysiology of metabolic syndrome and associated disorders. The
purpose of this review is to elucidate tissue-specific signaling pathways of adiponectin and possibly identify potential
therapeutic targets for MetS as well as to evaluate the potential of adiponectin as a biomarker/therapeutic option in
MetS.
Keywords: Metabolic syndrome, Adiponectin, AMPK, Vascular endothelial cell, Cardiomyocyte, VSMC
Introduction
Metabolic diseases including type 2 diabetes, obesity
and other cardiovascular diseases are becoming alarming throughout the entire world among people of all age
groups (~ 25% of all adults in the world) and causing millions of deaths each year [1]. In accordance with the prevalence of metabolic diseases like diabetes, cardiovascular
diseases (CVDs) and other comorbidities are increasing
day-by-day as well (relative risk of CVD is twofold in men
and threefold in women) [2]. Thus, finding a common
regulatory factor/mechanism which governs both metabolic conditions and associated CVDs will provide new
therapeutic options for managing them effectively. Adiponectin, a 244 amino acid adipocytokines, qualifies this
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criterion. Adiponectin is encoded by the ADIPOQ gene
in humans and is predominantly secreted by the adipocytes of brown adipose tissue. There are a wide range of
cells and tissues such as osteoblasts, parenchymal cells,
myocytes, epithelial cells, hepatocytes, and placental tissue that secret adiponectin in a small amount [3].
Four different forms of adiponectin have been identified in human plasma so far including low-molecular-weight (LMW) trimer, medium-molecular-weight
(MMW) hexamer, high-molecular-weight (HMW) oligomer and globular adiponectin (gAd) [4, 5]. Post translational modifications in adiponectin account for more
than eight isoforms of adiponectin [6]. The molecular
weight of LMW, MMW and HMW adiponectin are
67 kDa, 140 kDa and 300 kDa respectively. LMW adiponectin has a half-life of 32 min while MMW and
HMW adiponectin have a half-life of 83 min. The plasma
concentration of adiponectin in humans ranges from 2
to 20 µg/ml, which is around 1000-fold higher than the
plasma concentration of insulin [4]. A vast majority of
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studies suggest that HMW adiponectin is the predominant form contributing to the regulation of different
types of biological functions including insulin sensitivity, glucose uptake, and lipid metabolism [7]. Due to tissue specific variability in the expression of adiponectin
receptors and diversity of adiponectin isoforms, the tissue specific adiponectin signaling mechanism also varies.
In this review, we provide potential cellular mechanisms
through which adiponectin exerts its role in a wide range
of cell types.

Pleiotropic role of adiponectin
Adiponectin aided regulation of skeletal muscle function

Skeletal muscle contributes to almost half of the human
body mass and is primarily known for its role in physical movement, posture, and breathing. However, skeletal
muscle plays an active role in numerous metabolic pathways including carbohydrate, protein, and fat metabolism
and storage of glucose and proteins [8]. Loss of skeletal
muscle is associated with delayed recovery from illness
and wound healing, decreased resting metabolic rate,
higher chance of physical disability and higher health
care costs [8, 9]. Findings from several studies showed
that alterations of skeletal muscle mass (SMM) are associated with cardiovascular health and even different
muscle morphology [9, 10]. A recent finding from a population-based study demonstrated that skeletal muscle
mass is inversely proportional to the incidence of CVD
[9].
According to the earlier understanding, adiponectin
acts on skeletal muscle cells, secreted only from the adipose tissue as an endocrine manner. However, it has been
recently discovered that adiponectin is also produced
by the skeletal muscle cells, acting in an autocrine/paracrine manner through the stimulation of adiponectin
receptor (AdipoR) 1 and AdipoR2 [11, 12]. Adiponectin
plays protective roles in most of the tissue types. However, several studies implied that adiponectin plays both
protective and destructive roles in different skeletal muscle types. Adiponectin elevated intracellular C
 a2+ levels
in cultured C2C12 myocytes, which has been reversed
by siRNA-mediated knockdown of AdipoR1 [13], thus
implying calcium-mediated contractility in muscle cells is
regulated by adiponectin. Adiponectin-induced intracellular Ca2+ increases mitochondrial biogenesis in skeletal
muscle via C
 a2+/calmodulin-dependent kinase (CaMK)
activation followed by the activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC1α) (Fig. 1) [14]. A study by Yoon et al., showed
that adiponectin treated differentiated C2C12 cells dose
dependently increased the mRNA expression of AcylCoA oxidase (ACO) and carnitine palmitoyltransferase
1 (CPT1), two important genes for fatty acid oxidation
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in skeletal muscle, through the activation of peroxisome
proliferator-activated receptor α (PPARα). This study also
confirmed that adiponectin-induced activation of PPARα
in C2C12 cells is mediated via the activation of AMPactivated protein kinase (AMPK) and p38 mitogen-activated protein kinase (MAPK) which was confirmed by
suppression of PPARα activity when C2C12 cells were
co-treated with adiponectin and AMPK/p38 MAPK
inhibitors. Additionally, adiponectin is shown to inhibit
the activity of acetyl-CoA carboxylase (ACC), an endoplasmic reticular enzyme in eukaryotes that can inhibit
mitochondrial β-oxidation, through AMPK-mediated
pathway in C2C12 cells. Findings from this study suggest
that adiponectin increases fatty acid oxidation in skeletal
muscle cells through the activation of AMPK/MAPK/
PPARα signaling pathway (Fig. 1) [15].
Tibialis anterior muscle (TAM)-specific overexpression of both AdipoR1 and AdipoR2 increased phosphorylation of AMPK, protein kinase B (PKB/AKT) and
extracellular signal-regulated kinase (ERK) and subsequently increased the expression of the insulin responsive glucose transporter (GLUT)4 (Fig. 1). However,
overexpression of VEGFR2 alone in TAM, increased the
expression of PPARα and peroxisomal acyl-coenzyme
A oxidase (ACOX)1, the first enzyme of the fatty acid
β-oxidation (Fig. 1) [16]. Successive intravenous injections of AdipoRon, an agonist for AdipoR1 and AdipoR2,
in C57BL/6J mice decreased the weight gain and mean
muscle fiber cross-sectional area and the protein content in plantaris muscle (PLA), but not in soleus muscle (SOL). Additionally, knockdown of AdipoR1 and/
or AdipoR2 in C2C12 myotubes rescued AdipoRonassociated decrease in protein content in PLA, but not
in SOL. However, AdipoRon administration significantly
increased the phosphorylation of AMPK in both PLA
and SOL [17]. By employing the adiponectin knockout
(AdipoKO) mice, it has been demonstrated that adiponectin is involved in muscle activity as these Adipo KO
mice exhibited poor endurance exercise capacity compared with their age-matched wild-type controls [6, 18].
High-fat diet (HFD)-induced diabetes mellitus in rodents
impaired gastrocnemius muscle contractile parameters
(e.g. peak twitch tension, peak tetanic tension and half
relaxation time) by downregulating the gene expression of adiponectin and sarcoplasmic reticulum calcium
ATPase (SERCA), a crucial factor of intracellular Ca2+
homeostasis. However, adiponectin treatment in diabetic
rats increased the expression of SERCA, GLUT4 and adiponectin genes whereas it decreased the levels of serum
glucose, insulin, HOMA index, triglycerides, and cholesterol [19]. Also, adiponectin is shown to be associated
with increased muscle regeneration and decreased proteolysis which ultimately led to increased muscle mass
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Fig. 1 Role of adiponectin in skeletal muscle. Adiponectin-induced activation of AdipoR1/AdipoR2 and subsequent interaction with adapter
proteins, APPL1/APPL2, enhance fatty acid oxidation through MAPK-PPARα-mediated expression and activation of ACOX1 and AMPK-NAD+/
NADH-mediated response of ACC. Activated AdipoR1/AdipoR2 also increase mitochondrial biogenesis through APPL1-SERCA-Ca2+-CaMKKβ
or LKB1-AMPK-NAD+/NADH-SIRT1-mediated activation of PGC1α. Additionally, activation of adiponectin receptors enhances glucose uptake
via APPL1-Rab5 or APPL1-AMP-AMPK-mediated translocation of GLUT4 as well as attenuation of Rheb-mTOR-S6K1-induced inhibition of insulin
signaling

[20]. Sarcopenia, a pathological condition of progressive
muscle loss in aging [21] or cancer [22], is negatively
correlated with plasma adiponectin levels [23]. Serum
adiponectin levels were significantly lower in a cohort
of sarcopenic patients compared with their non-sarcopenic controls [24]. There are contradictory findings to
this notion; for instance, elevated adiponectin levels are
positively correlated with sarcopenic males with cardiovascular disease (CVD) relative to non-sarcopenic males
with CVD [25]. Plasma adiponectin levels were increased
significantly in spinal and bulbar muscular atrophy
patients compared to the healthy age-matched subjects [26]. Adiponectin is also associated with increased
translocation of fatty acids in skeletal muscle cells to fuel
β-oxidation process via increased expression of CD36, a
fatty acid transporter (Fig. 1) [4]. A significant decrease

in mitochondrial biogenesis and function in gastrocnemius muscles by decreasing the expression of PPARα and
PGC-1α [27] was observed in AdipoKO mice. The same
study also showed that both type 1 (oxidative) and type
2 (glycolytic) muscle fibers are reduced in the skeletal
muscle tissues of adipoKO mice. Also, treatment with
globular adiponectin decreased ROS formation in skeletal muscle cells [27]. Interactions between phosphotyrosine and an adaptor protein, with PH domain and leucine
zipper (APPL)1, which is a downstream signaling protein
in adiponectin receptors-mediated signal transduction
pathways, play an important role in insulin-mediated
signaling in skeletal muscle by activating insulin receptor
substrate (IRS) 1/2 [28].
Sirtuin1 (SIRT1) plays an important role in fatty acid
oxidation and mitochondrial biogenesis through PGC-1α
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acetylation and PPAR-α activation in skeletal muscle
[29]. It is also shown that adiponectin-induced increase
in intracellular C
 a2+ influx and activation of CaMKK,
AMPK, and SIRT1 were decreased in muscle-specific
AdipoR1 KO mice [30]. In skeletal muscle, adiponectininduced activation of tuberous sclerosis 1 (TSC1) inhibits the activity of Ras homolog enriched in brain (Rheb),
a negative regulator of insulin signaling as it suppresses
the activity of insulin receptor substrate-1 (IRS-1) (Fig. 1)
[31, 32]. Thus, it can be summarized that adiponectin
elicits its physiological and ameliorative function in skeletal muscles by modulating aforementioned signaling
pathways.
Adiponectin aided regulation of vascular smooth muscle
function

Vascular smooth muscle cells (VSMCs), key cells in
the vessel walls that regulate blood pressure. Their dysfunction may lead to pathological conditions including
hypertension, restenosis and atherosclerosis [33]. Adiponectin is an anti-atherogenic and anti-inflammatory
adipokine in atherosclerosis [34]. However, the mechanisms underlying the effect of adiponectin on VSMCs
are not clearly elucidated. AdipoR1 and AdipoR2 are
shown to be expressed in cultured human VSMC line
[35]. According to Ding et al., treatment with HMW
adiponectin is shown to induce human coronary artery
VSMCs differentiation as dictated by the upregulation
of contractile protein markers of VSMC differentiation,
including smooth muscle myosin heavy chain, h-caldesmon, calponin, and smooth muscle-α-actin [36]. They
also showed that HMW adiponectin treatment repressed
mechanistic target of rapamycin complex 1 (mTORC1)
and forkhead box protein O4 (FoxO4) through the activation of AMPKα2 in human coronary artery VSMCs
(Fig. 2) [36]. VSMCs also secret adiponectin to regulate
VSMC contractile phenotype in a autocrine/paracrine
manner, this is demonstrated in VSMCs isolated from
mice [37]. Contrary to the previous findings, Zhang et al.
reported that adiponectin treatment inhibits the proliferation and migration of cultured human coronary artery
VSMCs [38]. They also reported that adiponectin treatment stimulates apoptosis by modulating mitofusin-2
(MFN2)-mediated Ras-Raf-Erk1/2 signaling pathway
(Fig. 2) [38]. Findings from these studies suggest that adiponectin inhibits neointimal formation in pathological
conditions where excessive proliferation and numbers of
VSMCs are deleterious, through suppressing the proliferation and migration as well as enhancing apoptosis of
VSMCs.
A study aimed to determine the role of adiponectin and
its receptors in angiotensin II (Ang II)-induced vascular injury [35]; the findings from the study suggest that
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adiponectin treatment significantly attenuated Ang IIinduced VSMCs migration and p38 phosphorylation [35].
Additionally, treatment with AdipoRon attenuated Ang
II-induced hypertensive vascular hypertrophy and fibrosis [35]. Another study using rat aortic tissue showed that
adiponectin pretreatment before Ang II challenge attenuated Ang II-mediated hypertrophic effect in VSMCs
through the inhibition of RhoA/ROCK pathway and
subsequent ROS formation (Fig. 2) [39]. Thus, it appears
adiponectin works as a protective molecule in Ang IIinduced hypertension following vascular remodeling.
Adiponectin aided regulation of cardiac muscle function

Cardiomyocyte is the key cell type of the heart tissue, as
it is responsible for cardiac contractility and relaxation,
the primary function of the heart. Most cardiac diseases including heart failure (HF), cardiomyopathy and
myocardial infarction (MI) are directly associated with
impaired contractile function/death of cardiomyocytes
[40]. Metabolic diseases like obesity and type 2 diabetes
mellitus (T2DM) are strongly associated with heart diseases such as atherosclerosis, coronary artery disease
(CAD), MI and HF [41]. Several studies in humans and
rodents confirmed that obesity [42], T2DM [43], hypertension [44], atherosclerosis [45], CAD [46], MI [47] and
HF [46] are associated with reduced plasma adiponectin
levels and/or impaired adiponectin signaling in target tissues. Cardiomyocytes are known to secrete adiponectin
in a paracrine/autocrine manner, although this level is
relatively low compared with the levels produced by the
adipose tissue [48, 49]. Several studies reported that adiponectin receptors are expressed in human cardiomyocytes, murine derived atrial cardiomyocytes and neonatal
rat ventricular cardiomyocytes [48, 50]. Adiponectin is
known to exert its cardioprotective role on cardiomyocytes through the activation of AdipoR1 and AdipoR2
[49]. Adiponectin improved contractility of cardiomyocytes isolated from db/db obese mice through the activation of AdipoR1/AdipoR2 [51]. Cao et al., revealed that
globular adiponectin attenuated Ang II-induced atrial
hypertrophy through the activation of AdipoR1/APPL1
signaling pathway and subsequent decrease in NF-κB
activation and translocation into the nucleus in rat atrial
cardiomyocytes [52]. They also reported that activation
of AdipoR1/APPL1 upregulated the expression and/or
activation of downstream signaling molecules including
PI3K, AMPK and NF-ĸB in rat atrial cardiomyocytes [52].
SiRNA-mediated knockdown of AdipoR1 and/or AdipoR2 attenuated C1q tumor necrosis factor-alpha-related
protein 9 (CTRP9)-mediated inhibition of ROS formation and increased apoptosis of cardiomyocytes in H9C2
rat cardiomyoblast cell line [53]. Cardiomyocyte-specific
PPARγ overexpressing mice showed a significant increase
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Fig. 2 Role of adiponectin in VSMC. Adiponectin enhances apoptosis and inhibits the proliferation of VSMCs through AdipoR1/dipoR2-mediated
activation of MFN2-Ras-Raf-Erk1/2 signaling pathway in pathological condition. Adiponectin-induced activation of AMPK attenuates
mTORC1-S6K1-mediated inhibition of insulin signaling and subsequently increases protein synthesis and attenuates FoxO4-mediated inhibition of
VSMC proliferation in atherosclerosis. Adiponectin-induced production of endothelial NO also diffuses into the VSMCs and subsequently inhibits the
activation of RhoA protein, an upstream factor that induces VSMC hypertrophy through ROCK-Cofilin-mediated increase in F-actin/G-actin ratios
following the formation of ROS

in adiponectin production in an autocrine manner and
subsequently protect cardiomyocytes from hypertrophy
that dictates PPARγ a downstream signaling molecule of
adiponectin expression in cardiomyocytes [54]. Another
study concluded that exenatide, a 39-amino-acid peptide and a synthetic version of exendin-4 hormone which
is used as an anti-diabetic medication, prevented the
apoptosis of isolated cardiomyocytes from diabetic rats
via upregulating the expression of adiponectin, APPL1,
p-AMPK and PPARα and downregulating the expression of NFκB [55]. Pretreatment with recombinant rat
adiponectin before Ang II stimulation, promoted AMPK
phosphorylation and inhibited ERK1/2 activation in

neonatal rat ventricular myocytes (NRVMs) [56]. Adiponectin treatment is shown to upregulate the expression of miR-133a, a key regulator of cardiac hypertrophy
through AdipoR1/AMPK activation and ERK1/2 inhibition in NRVMs [56]. Adiponectin has been shown
to induce actin cytoskeleton remodeling to mobilize
GLUT-4 mediated increased glucose uptake through the
activation of APPL1/Rho/Rho-associated protein kinase
(ROCK) signaling pathway in neonatal rat cardiomyocytes (Fig. 3) [57]. Adiponectin promotes the activation of
AdipoR1/APPL1/AMPKα2 signaling and inhibits acetylCoA carboxylase (ACC) activity through phosphorylation and subsequently increases fatty acid oxidation in rat
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Fig. 3 Adiponectin signaling in Cardiomyocyte. Adiponectin-induced activation of AdipoR1 or AdipoR2, triggers LKB1-mediated activation
of AMPK that prevents cardiac hypertrophy by inhibiting Nuclear factor-κB (NF-ĸB), reactive oxygen species (ROS) formation and extracellular
signal-regulated kinase (ERK) and by stimulating fatty acid oxidation. Adiponectin-induced AMPK also prevents inflammation-mediated myocardial
infarction through the activation of endothelial nitric oxide synthase (eNOS) as well as prevents diabetic cardiomyopathy via increasing fatty
acid oxidation. Adiponectin-induced activation of ceramidase (CDase) prevents apoptosis of cardiomyocytes and subsequent development
of cardiac hypertrophy through the degradation of ceramides. Activated AdipoR1/AdipoR2 prevents diabetic cardiomyopathy through
APPL1-Rho-ROCK-mediated elevation of glucose uptake. Adiponectin-induced activation of Sphk-1-COX-2 cascade prevents myocardial infarction
through the inhibition of TNF-α-mediated inflammation. Adiponectin-induced activation of PPARγ increases the transcription of adiponectin in
cardiomyocytes

cardiomyocytes (Fig. 3) [58]. Additionally, adiponectin
increases cluster of differentiation 36 (CD36) translocation and fatty acid uptake as well as AKT phosphorylation and insulin-induced glucose transport in primary
cardiomyocytes (Fig. 3) [58]. Adiponectin-induced activation of AMPK has been shown to share its cardioprotective role with Sirtuin 1 (Sirt1). A recent study showed
that adiponectin-induced activation of AMPK/Sirt1
signaling contributes to the preconditioning of myocardial ischemia–reperfusion (IR) injury in rats [59]. Adiponectin treatment is shown to induce the activation of
ceramidase (CDase) and subsequently prevents apoptosis
of isolated ventricular cardiomyocytes from obese mice
through the degradation of ceramides [60]. Adiponectin

has been shown to involve myocardial ischemic postconditioning (IPo)-mediated cardioprotection against myocardial ischemia–reperfusion (IR) injury in rodents via
both AMPK-dependent nuclear and AMPK-independent
mitochondrial signal transducer and activator of transcription (STAT)3 activation [61]. Adipo KO mice exhibited enhanced myocardial apoptosis, infract size, levels of
nitric oxide (NO), inducible nitric oxide synthase (iNOS),
superoxide, and their cytotoxic reaction products, peroxynitrite, in cardiac tissues [62]. On the other hand, adiponectin treatment markedly decreased iNOS protein
expression and NO/superoxide production, blocked peroxynitrite formation and attenuated the progression of
atherosclerotic lesions in carotid artery of ApoE−/− mice
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[63]. Intraperitoneal injection of a single dose of doxorubicin, a cardiotoxic chemotherapeutic agent, was shown
to significantly increase mortality and exacerbated left
ventricular contractile dysfunction in adipo KO mice
compared with age-matched doxorubicin-injected WT
control [64] while adiponectin treatment was shown to
ameliorate doxorubicin-mediated cardiotoxicity through
Akt activation in NRVMs [64]. Induction of MI increased
the cardiac levels of COX-2, a cardioprotective molecule,
in wild type mice which was inhibited in adiponectindeficient mice. By using primary rat cardiomyocytes, adiponectin was shown to increase COX-2 level, however
to determine the signaling mechanism of whether adiponectin augments COX-2 expression through a sphingosine kinase-1 (SphK-1)-dependent pathway, the cardiac
myocytes were pretreated with a SphK-1 inhibitor (SKI)
followed by incubation with adiponectin or vehicle. It
was found that adiponectin-mediated COX-2 upregulation was diminished by 38% by preincubation with SKI.
This was again confirmed by treating the cardiomyocytes
with SiRNA of SphK-1 before treating with adiponectin
as the results revealed that adiponectin-induced COX-2
expression was decreased by SiRNA of SphK-1 by 43%
compared to control RNA. Thus, it can be summarized
that adiponectin activates sphingosine kinase-1 (SphK1)/COX-2 signaling in cardiomyocytes and thus contributes to the cardioprotection in myocardial inf arction
(Fig. 3) [65, 66].
Adiponectin aided regulation of vascular endothelial cell
function

The vascular endothelial cells (ECs) plays an indispensable role in the cardiovascular system as they serve
as a protective barrier between blood and vessel walls,
as well as secrete a plethora of bioactive substances
including vasoactive substances, enzymes, growth factors, cytokines and chemokines [67]. Impaired functioning of the vascular ECs due to oxidative and shear
stress, systemic hypertension, elevated levels of free
fatty acids, pathogenic infection and intake of hazardous chemicals can cause severe consequences in
cardiovascular physiology including coronary artery
disease (CAD), MI, cardiomyopathy, HF, atherosclerosis and arteriosclerosis [68]. One of the most important factors that maintain cardiovascular homeostasis
by controlling NO bioavailability is endothelial nitric
oxide synthase (eNOS). The broad range of activities
of eNOS in vascular ECs largely depends on posttranslational modifications, including acylation, nitrosylation, phosphorylation, acetylation, glycosylation and
glutathionylation [69]. Activation of eNOS-NO signaling is associated with several cardiovascular functions
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including upregulation of EC angiogenesis, mitochondrial biogenesis, cell–cell communication, vasodilation
and telomerase activity and downregulation of oxidative stress, shear stress and infiltration of inflammatory
cells [70]. Adiponectin has been shown to induce the
phosphorylation of eNOS at S
 er633 [71] and S
 er1177 and
generation of NO in human umbilical vein endothelial
cells (HUVECs) through AdipoR1/R2-APPL1/AMPKmediated pathway (Fig. 4) [72]. Interaction between the
heat shock protein (HSP) 90 and eNOS is required to
produce NO in ECs which was confirmed by Amour
et al. through a study where pharmacological inhibition
of HSP90 activity attenuated Isoflurane-dependent NO
production in human CECs (Fig. 4) [73]. Globular adiponectin treatment dose-dependently increased NO in
bovine aortic endothelial cells (BAECs). NO generation
was elicited by stimulating the binding of HSP90 with
eNOS and subsequently activation of PI3-AKT signaling pathway to over activate eNOS. It was shown that
pharmacological inhibition of HSP90 or PI3K in BAECs
decreased globular adiponectin-mediated NO release.
This globular adiponectin also increased endothelial
cell-dependent vasorelaxation in rat aortic rings [74].
Treatment with globular adiponectin (5 μg/ml) inhibited palmitate-induced ROS generation and subsequent
induction of apoptosis in HUVECs. Using pharmacological interventions for cyclic AMP (cAMP) and
AMPK, this study also showed that adiponectin inhibits the generation of ROS and subsequent induction of
apoptosis in HUVECs through cAMP/PKA and AMPK
mediated signaling pathway (Fig. 4) [75]. Transcription factor NF-ĸB signaling plays a central role in the
transcription of several proinflammatory cytokines and
growth factors that are associated with the pathogenesis of several diseases including atherosclerosis [76].
Adenoviral transduction of adiponectin gene attenuated the formation of atherosclerotic plaques in the
aortic arch of A
 poE−/− mice through the inhibition of
NF-ĸB pathway (Fig. 4) [77]. Treatment with globular
adiponectin has been shown to increase human microvascular ECs migration, proliferation and angiogenesis
through upregulating the expression of proangiogenic
factors including matrix metalloproteinase (MMP)-2,
MMP-9 and VEGF. Adiponectin-induced upregulated
expression of VEGF is mediated via the activation of
AdipoR1, and MMP-2 and MMP-9 are mediated via
the activation of both AdipoR1 and AdipoR2 [78]. Adiponectin appears to play an important role in mitochondrial biogenesis in vascular ECs as evident by a
study where Adipo KO mice downregulated the expression of regulatory proteins of mitochondrial biogenesis including PGC-1α, nuclear respiratory factor 1,
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Fig. 4 Adiponectin signaling in vascular endothelial cell. Adiponectin binds with its receptors, AdipoR1/AdipoR2, which in turn activate
the downstream signaling molecules. Activation of AdipoR1 or AdipoR2 induces eNOS activation through PI3K/AKT signaling pathway and
subsequently increases EC angiogenesis, mitochondrial biogenesis, cell–cell communication, vasodilation and telomerase activity, whereas it
decreases oxidative stress, shear stress, infiltration of inflammatory cells and apoptosis. Adiponectin-induced activation of APPL1-cAPM-PKA-AMPK
inhibits NF-ĸB-mediated expression of proinflammatory factors including plasminogen activator inhibitor-1 (PAI-1), interleukin 8 (IL-8), vascular cell
adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and E-Selectin

transcription factor A, Sirt3 and Sirt1 in pulmonary
vascular ECs [79].
Adiponectin aided regulation of hepatocyte function

Hepatocytes, the major cell types in the liver that derived
from parenchyma, contribute to the ~ 80% mass of the
liver tissue and play indispensable roles in metabolism,
detoxification, protein synthesis and activation of the
innate immune system [80]. In hepatocytes, adiponectin mainly contributes to the regulation of glucose and
fat metabolism through an insulin-sensitizing effect. The
role of adiponectin in healthy liver includes a decrease
in gluconeogenesis, lipid biosynthesis, inflammation,
and oxidative stress, and an increase in insulin sensitivity and fatty acid oxidation [81]. Adiponectin confers its

biological effects in hepatocytes through the activation
of AdipoR1 and AdipoR2 [82]. A review has summarized
a large number of studies to report that adiponectininduced decrease in gluconeogenesis is regulated mainly
through the activation of the liver kinase B1 (LKB1)/
AMPK axis in hepatocytes [83]. Adenoviral transduction
of constitutively active form of AMPK has been shown
to decrease the rate of gluconeogenesis through sequestering the expression and activities of two rate-limiting
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in
primary rat hepatocytes [84, 85]. Transcriptional profiling result from another study showed that treatment with
5-aminoimidazole-4-carboxamide riboside (AICAR), an
AMPK activator, upregulated the transcription of two
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downstream targets of AMPK, early growth response
1 (EGR1) and dual-specificity protein phosphatase 4
(DUSP4) in AML12, H4IIE, and Fao cells. This finding was
again confirmed by measuring mRNA and protein levels
of EGR1 and DUSP4 in rat hepatoma cell lines, H4IIE
and Fao. Using a reporter gene assay and real-time qPCR,
this study further demonstrated that exogenous DUSP4
inhibits the promoter activity and expression of both
PEPCK and G6Pase in H4IIE cells [86]. Some reviews
have summarized a large number of studies to report
that adiponectin-induced activation of AMPK in hepatocytes is mediated via PLC/Ca2+/CaMKK signaling pathway [82, 87]. Administration of adiponectin decreased
fat accumulation in the liver of +Leprdb/+Leprdb (db/db)
mice as well as in cultured Fao cell lines. This action of
adiponectin is predominantly associated with the activation of the AdipoR1/LKB1/AMPK signaling pathway and
subsequent downregulation of sterol regulatory elementbinding protein 1c (SREBP1c), a master regulator of fatty
acid synthesis in the liver. The involvement of AdipoR1/
LKB1/AMPK signaling in adiponectin-induced downregulation of SREBP1c was further confirmed in LKB1
KO (LKB1lox/lox) mice, where the absence of LKB1 rescued the inhibitory effect of adiponectin on SREBP1c
expression [88]. However, a review demonstrated that
adiponectin-induced AMPK activation in hepatocytes is
much lower than other cell types [89]. Adiponectin lowers the rate of gluconeogenesis in hepatocytes not only
through the activation of LKB1/AMPK signaling pathway but also through other pathway/s independent of
LKB1/AMPK activation [90]. Findings from this study
were confirmed in mice with inducible hepatic deletion of LKB1. This study showed that deletion of LKB1
in the liver partially impaired glucose-lowering effects of
adiponectin in LKB1lox/lox mice. However, adiponectininduced downregulation of gluconeogenic and lipogenic
gene expression including Ppargc1a, Glucose-6-phosphatase catalytic subunit, Phosphoenolpyruvate carboxykinase 1, SREBP1c, acetyl-CoA carboxylase (ACC)
alpha, ATP citrate synthase, and fatty acid synthase
(FAS) in and decreased hepatic glucose production was
preserved in the liver of LKB1lox/lox mice [90]. Review
with a large number of research findings demonstrated
that adiponectin increases β-oxidation in hepatocytes
through the activation of AdipoR1/LKB/AMPK signaling pathway as well as increased activation of PPARαinduced upregulation of acyl CoA oxidase (ACO) and
UCP2. Adiponectin-induced inhibition of ACC-1 transcription followed by the activation of carnitine palmitoyl transferase-1 (CPT-1) facilitates fatty acid transport
into the mitochondria for β-oxidation (Fig. 5) [89]. Adiponectin-induced activation of AdipoR1 or AdipoR2
prevents hepatocellular ceramide accumulation through
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increased activation of ceramidase (CDase) and thereby
may attenuate ceramide-mediated insulin resistance
and hepatocyte apoptosis (Fig. 5) [60]. This finding was
confirmed with increased CDase activity and decreased
ceramide accumulation in liver-specific AdipoR1 and/
or AdipoR2 overexpressing mice liver [91]. Treatment
with fibroblast growth factor 21 (FGF21), an important
regulator of metabolism and energy homeostasis significantly decreased ceramide accumulation in hepatocytes
of obese mice through increasing the expression of adiponectin, which leads to the restoration of euglycemia
and reduced hyperlipidemia. The finding of this study
was further confirmed when the effects of FGF21 were
blunted in AdipoKO mice [92]. A study in AdipoKO
mice has been shown to increase abnormal mitochondrial morphologies, decrease the oxidative activities of
mitochondrial respiratory chain (MRC) complexes as
well as decrease the expression of mitochondrial uncoupling protein 2 (UCP2) in the liver tissues relative to their
age-matched control (Fig. 5). In the same study, the role
of adiponectin in liver mitochondria was further confirmed when adenovirus-mediated replenishment of adiponectin in AdipoKO mice liver significantly decreased
lipid accumulation, restored the oxidative activities of
MRC complexes and reduced the formation of lipid
peroxidation products compared with control mice.
Although, there were no significant effects on hepatocellular mitochondrial biogenesis and ROS production
in adiponectin replenished liver in AdipoKO mice [93].
Adiponectin is reported to ameliorate D-galactosamine/
lipopolysaccharide (GalN/LPS)-induced liver injury in
KK-Ay obese mice. A study reported that GalN/LPSinduced liver injury is associated with systemic elevation of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), two important biomarkers of
liver damage, increased levels of systemic and hepatocellular TNF-α, and/or showed a high degree of lethality
in KK-Ay obese mice. Intraperitoneal administration of
adiponectin before GalN/LPS challenge, ameliorated the
GalN/LPS‐induced elevation of systemic AST and ALT
levels, systemic and hepatocellular TNF-α levels as well
as a reduction in lethality in KK-Ay obese mice. Additionally, adiponectin pretreatment increased the expression of PPARα mRNA in the liver of obese mice (Fig. 5)
[94]. A study in 47 NAFLD patients showed systemic
elevation of TNF-α, monocyte chemoattractant protein
(MCP)-1 and IL-6 levels and decrease in adiponectin levels in both males and females [95]. Therefore, it can be
surmised that adiponectin works as an anti-inflammatory
molecule by lowering the hepatocellular proinflammatory cytokine levels. Cumulative findings from a review
demonstrated that adiponectin-induced activation of
antioxidant enzymes, superoxide dismutase (SOD)1 and
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Fig. 5 Role of adiponectin signaling in the liver. Binding of adiponectin with AdipoR1 activates AMPK via APPL1/LKB1 or APPL1/PLC/Ca2+/
CaMKK mediated signaling pathways. Activated AMPK subsequently inhibits the activities of PEPCK and G6Pase through the activation of EGR1
and DUSP4, which leads to decreased gluconeogenesis. Activated AMPK also decreases lipid biosynthesis through inhibiting sterol regulatory
element-binding transcription factor 1c (SREBP1c)-mediated transcription of acetyl-CoA carboxylase (ACC), FAS and stearoyl-CoA desaturase (SCD)1.
Additionally, activated AMPK increases abnormality in mitochondrial morphologies and fatty acid oxidation via sequestering the inhibitory effect
of ACC-1 on carnitine palmitoyltransferase (CPT)-1 activation. Independent of AMPK activation, adiponectin also increases insulin sensitivity
through the activation of AdipoR1 or AdipoR2 following CDase-mediated degradation of ceramides. Upon activation of AdipoR2 with the binding
of adiponectin, fatty acid oxidation increases through PPARα-induced activation of acyl-CoA oxidase (ACO) and uncoupling protein (UCP)2.
Adiponectin-induced activation of AdipoR1 contributes to the activation of antioxidant enzymes, superoxide dismutase (SOD)1 and catalase which
subsequently decreases oxidative stress via downregulating ROS production. Adiponectin also protects hepatocytes through the inhibition of
ROS-mediated activation of proinflammatory molecules including TNF-α and MCP1

catalase contribute to hepatoprotection through the inhibition of ROS-mediated production of proinflammatory
molecules and subsequent reduction of oxidative stress
(Fig. 5) [96].
Adiponectin aided regulation of pancreatic islet function

Around 50–70% of the human pancreatic islets are β cells
which are known to play a profound role in metabolism
through the production, storage and secretion of insulin and amylin, two major peptides that regulate glucose
homeostasis in circulation [97]. Since the cell signaling mechanism of adiponectin is associated mostly with
insulin-dependent tissues, a handful of metabolic studies

focus on the role of adiponectin in pancreatic islet cells.
However, due to the lack of substantial findings, the role
of adiponectin signaling in pancreatic α and β-cells are
not completely known yet. Adiponectin exerts its biological effect on pancreatic β-cells through the activation of
both AdipoR1 and AdipoR2, although AdipoR1 predominantly expressed in β-cells and globular adiponectin has a
higher affinity for AdipoR1 [98–100].
A study by Okamoto et al., showed that administration
of full-length adiponectin facilitates insulin secretion
from both isolated and intact pancreatic islet in C57BL/6
mice by enhancing exocytosis of insulin granules without
affecting ATP generation, membrane potentials, cytosolic
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Ca2+ concentrations or activation status of AMPK. This
study also showed that adiponectin-induced activation of AMPK inhibits glucose-stimulated lipogenesis
in MIN6 beta cells (Fig. 6) [101]. Adiponectin treated
isolated islets from rats for 24 h, increased the mRNA
expression of PPARγ and pancreatic and duodenal homeobox (Pdx)-1, a key transcription factor that regulates
early pancreas formation as well as glucose-mediated
insulin secretion from β-cells (Fig. 6) [102]. Treatment
with globular adiponectin for 24 h prevented apoptosis,
increased β-cell viability, upregulated the expression of
insulin genes (Ins I and Ins II) and secretion of insulin as
through the activation of AKT and ERK in both MIN6
beta cells and isolated islets from mice. Findings from
this study were further confirmed when the adiponectininduced decrease in apoptosis, increased β-cell viability,
upregulation of insulin gene expression and secretion of
insulin were prevented with the use of dominant-negative Akt, PI3K inhibitor and MEK inhibitor. This study
also showed that adiponectin treatment upregulated the
expression of transcription factors Pdx1 and MafA in
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isolated mouse islets (Fig. 6) [100]. According to Ye and
Scherer, adiponectin overexpressing mice with inducible acute β-cell ablation has been shown to regenerate
pancreatic β-cells as well as mitigate local lipotoxicity by
upregulating the transcription of two key transcription
factors, hepatocyte nuclear factor 4α and PPARα [103].
Another study and a review by the same research group
revealed that adiponectin induces fat tissues to uptake
fat molecules from bloodstreams and subsequently lowers circulatory cholesterol levels in β-cell-deficient mice.
This study also demonstrated that both insulin and adiponectin double deficient mice died after developing
hypercholesterolemia. Findings from the studies suggest
that a lack of adiponectin in insulin-deficient mice aggravates insulin-mediated lipoatrophy and hyperlipidemia to
lethal levels [104, 105]. Contrary to this finding, a study
showed that adiponectin (5 µg/ml) treated normal islets
isolated from healthy mice had no significant effect on
insulin secretion. Although, adiponectin (5 µg/ml) treatment inhibited insulin secretion in islets isolated from
insulin resistant mice at 2.8 mM glucose exposure but

Fig. 6 Role of adiponectin signaling in pancreatic β-cell. Adiponectin-induced activation of its receptors, AdipoR1 or AdipoR2, increases insulin
secretion by increasing the transcription of insulin gene (INS) through the upregulation of transcription factors pancreatic and duodenal homeobox
(Pdx)1 and MafA as well as increasing exocytosis of insulin granules. Adiponectin decreases the rate of hyperglycemia and lipogenesis through the
activation of AMPK. Adiponectin-induced activation of AMPK also increases fatty acid oxidation through the inhibition of acetyl-CoA carboxylase
(ACC). Adiponectin-induced activation of both MEK-ERK1/2 and PI3-AKT signaling pathways increase β-cell viability and decrease β-cell apoptosis
through the inhibition of IL-1β, IFN-γ, palmitate and hyperglycemia
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augmented insulin secretion at 16.7 mM glucose exposure. Based on these findings, it can be concluded that
dichotomous action of adiponectin on pancreatic islets is
due to the lack of exact in vivo environments that mimic
the underlying pathological conditions like obesity or
insulin resistance [106].
Adiponectin aided regulation of bone function

There are three types of bone cells that contribute to the
process of bone formation: osteoblasts, osteoclasts and
osteocytes. Remodeling of the bone is governed by an
intricate balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. When
the balance leans toward osteoblast number/activity, it
causes an increase in bone mineral density (BMD) by
lowering the number of osteocytes. On the other hand,
when the balance leans toward osteoclast number/activity, it causes a decrease in BMD by decreasing the number of osteocytes [107]. There are limited studies that
determine the role of adiponectin in bone cells. BMD
data from the lumbar spine (L1–L4 together) and the hip
(femoral neck) in a cohort of 92 participants showed that
circulatory adiponectin levels decreased significantly in
older men (60–80 years) with decreased BMD
(BMI > 27 kg/m2) compared to older men (60–80 years)
with normal BMD (BMI < 27 kg/m2) [108]. A study in
rabbits with mandibular osteodistraction (distraction
rate = 2 mm/day) showed that intermittent administration of adiponectin (2 µg) into the distraction gap promoted much greater bone formation, higher BMD and
bone mineral content (BMC) compared with vehicletreated rabbits after six weeks [109]. Administration of
adiponectin overexpressing adenovirus in the jugular
vein of 8-week-old C57BL/6 J male mice showed significantly larger trabecular bone volume compared with the
vehicle-treated mice after 2 weeks. Additionally, treatment with recombinant adiponectin attenuated macrophage colony-stimulating factor/receptor activator of
nuclear factor-κB ligand-induced differentiation of bone
marrow stromal cells and human CD14-positive peripheral blood mononuclear cells (PBMCs) into osteoclasts as
well as significantly reduced the resorption area of CD14positive PBMCs relative to the control in a dose-dependent manner. Adiponectin-treated MC3T3-E1 osteoblasts
significantly increased the mRNA expression of alkaline
phosphatase (ALP), an important biomarker of osteoblast differentiation, and the matrix mineralization on
day 12 and 18 compared with the control. Findings from
this study suggest that adiponectin treatment decreases
osteoclast differentiation and increases osteoblast differentiation and bone mineralization [110]. Intracerebroventricular administration of adiponectin increases
serum epinephrine and norepinephrine levels as well as
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osteoclast numbers whereas increases trabecular bone
mass as well as the number of osteoblasts in both WT
and adiponectin-KO mice. Additionally, central administration of adiponectin significantly increased some neuropeptides
including
hypothalamic
tryptophan
hydroxylase 2 (TPH2) and 5-hydroxytryptamine receptor
2C (5-HTR2C). However, pharmacological stimulation of
sympathetic activity with isoproterenol, a β-adrenergic
agonist, attenuated adiponectin-mediated effects. These
findings reveal that adiponectin increases bone mass
through the suppression of sympathetic tone [111]. A
study by Luo et al., showed that sustained release of adiponectin for 4 weeks in hydroxyapatite (HA) implanted
ovariectomized (OVX) rabbits significantly increased
peri-implant osteogenesis compared with controls and
short-term adiponectin treated groups. They also showed
that sustained release of adiponectin in rabbit mature
osteoclast culture significantly decreased the levels of
tartrate-resistant acid phosphatase and F-actin, two
important histochemical markers of osteoclasts, and
eventually decreased the activity of osteoclasts compared
to controls as well as short-term adiponectin treatment
[112]. Adenovirus-mediated transfection of adiponectin
in rat bone mesenchymal stem cells (BMSCs) significantly increased the expression of AdipoR1 and AdipoR2.
Treatment with adiponectin for 12 h significantly
increased the mRNA expression and protein levels of
β-catenin and cyclinD1, two important factors in Wnt/βcatenin signaling in cultured BMSCs. Adiponectin treatment for 3 and 7 days significantly increased the mRNA
expression of some osteogenic genes including ALP, osteocalcin (OCN), bone morphogenetic protein-2 (BMP-2)
and runt-related transcription factor-2 (RUNX2) in cultured BMSCs. Additionally, endogenous expression of
adiponectin via intramuscular adenoviral delivery significantly increased the expression/activation of OCN, BMP2, RUNX2 and ALP in isolated rat BMSCs (Fig. 7).
Findings from this study suggest that adiponectin inhibits
osteoclast-mediated bone resorption, increases osteoblast-mediated bone formation, and subsequently
improves bone density [113]. A study by Huang et al.,
showed that adiponectin treatment increased the mRNA
expression and protein levels of BMP-2, an important
factor for bone remodeling, in both cultured human osteoblast-like cell lines including hFOB and murine primary
osteoblastic cells. They confirmed the involvement of
AdipoR1 in adiponectin-mediated BMP-2 expression as
adiponectin treated osteoblast significantly increased the
mRNA expression of AdipoR1. This finding was further
confirmed when AdipoR1 siRNA treatment abolished
adiponectin-induced expression of BMP-2 in the hFOB
cell line. They also confirmed the involvement of AMPK,
p38 and NF‐κB in adiponectin-induced BMP-2
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Fig. 7 Role of adiponectin in bone marrow-derived stem cells. Adiponectin increases osteoblast differentiation through AdipoR1-AMPK-P38-NF-ĸB
signaling pathway-mediated expression and activation of COX-2. Adiponectin-induced activation of P38 also contributes to osteoblast
differentiation through the activation of JNK. Adiponectin signaling increases osteogenesis through the activation of Wnt/β-cat-mediated
expression of osteogenic genes including OCN, BMP-2, RUNX2 and ALP. Adiponectin-induced activation of AdipoR1-CK2-SMAD1/5/8 upregulates
the transcription and activation of SDF-1 and subsequently increases the migration and recruitment of BMSCs

expression when treatment with specific pharmacological inhibitors and siRNA blunted the effect of adiponectin in BMP-2 expression in osteoblasts. Findings from
this study suggest that adiponectin-induced upregulation
of BMP-2 in osteoblasts is carried out through the activation of AdipoR1/AMPK/p38/NF-ĸB signaling pathway
(Fig. 7) [114]. Another study showed that adiponectintreated mesenchymal stem cell (MSC) line C3H10T1/2
and mouse PBMCs significantly increased the mRNA
expression of ALP, OCN, OPN and type 1 collagen. This
study also showed that adiponectin treatment for 3 h significantly increased the mRNA expression and protein
levels of cyclooxygenase (COX)-2, an important marker
for osteoblast differentiation, as well as increased the levels of prostaglandin E2 (PGE2), the product of COX2, in
C3H10T1/2 and mouse primary bone marrow cells. Adiponectin treated C3H10T1/2 cells also increased the

mRNA expression of c‐Jun, an important transcriptional
activator of COX2 promoter, and ChIP assay deciphered
the involvement of c-Jun in COX2 promoter activity.
Additionally, adiponectin increased the phosphorylation
of c-Jun through the activation of p38 MAPK as confirmed by kinase assay when adiponectin treatment augmented the phosphorylation of both p38 MAPK and
c-Jun. This finding was further confirmed by decreased
phosphorylation of c-Jun when C3H10T1/2 cells were
co-treated with p38 MAPK inhibitor. During osteogenesis, adiponectin exerts its role in MSC through the activation of AdipoR1, which was confirmed by decreased
phosphorylation of p38 MAPK and COX2 expression
when C3H10T1/2 cells were treated with AdipoR1
siRNA. Adiponectin-induced upregulation of BMP-2 is
also mediated through the activation of COX2 which was
confirmed by decreased expression of BMP-2 when
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C3H10T1/2 cells were co‐treated with COX2 inhibitor.
Findings from this study revealed that adiponectin augmented osteoblast differentiation through AdipoR1/p38
MAPK/c-Jun-mediated transcription of cyclooxygenase
(COX)-2 and subsequent upregulation of BMP-2 in mesenchymal progenitor cell (Fig. 7) [115]. To study the role
of adiponectin in osteoblast retention ability within the
bone marrow or at the injured bone site, Yu et al., showed
that primary BMSCs isolated from 6‐week‐old APN−/−
mice decreased the expression of stromal cell-derived
factor (SDF)-1 that mediates the retention and mobilization of stem cells. They also found that adiponectin
(10 µg/ml) treated BMSCs isolated from WT mice
increased MMP9 mRNA expression around tenfold and
subsequently increased their migration. Additionally, the
study revealed that systemic administration of adiponectin is shown to improve calvarial bone defects in DIO
mice after 14 days. Also, they confirmed the involvement
of SMAD1/5/8 activation in adiponectin-induced SDF-1
upregulation by repressing the expression of SDF-1 when
MC3T3‐E1 cells were co-treated with adiponectin and
SMAD1/5/8 inhibitor. Furthermore, they deciphered that
adiponectin‐dependent Smad1/5/8 phosphorylation
depends on the interaction between AdipoR1 and casein
kinase II (CK2). Findings from this study suggest that
adiponectin increases retention and mobilization of
BMSCs and subsequently increases bone regeneration
through AdipoR1/CK2/SMAD1/5/8-mediated upregulation of SDF-1 (Fig. 7) [116].

Adiponectin as a biomarker and a therapeutic
target
Studies in both humans and animals show that circulatory adiponectin levels are negatively correlated with
various pathological conditions including CVDs, T2DM,
obesity, insulin resistance, NAFLD, atherosclerosis, cardiomyopathy and HF [117]. Decreased levels of circulatory adiponectin are associated with a greater risk of
morbidity and mortality in patients with CVDs, whereas
increased circulatory adiponectin levels are cardioprotective [117]. A cohort study showed that elevated levels
of circulatory adiponectin are associated with a reduced
risk of developing T2DM and subsequent reduction in
cardiovascular risk [118]. Consistent with this finding,
the cardioprotective role of adiponectin is also revealed
by other studies where chronic low levels of circulatory
adiponectin is associated with the development of MI
and subsequent development of cardiovascular complications in both men and women [119]. Contrary to these
findings, other studies reported that hyperadiponectinemia is associated with increased risk of HF and acute
coronary syndrome in both men and women [120] as
well as increase the severity of post-stroke outcomes
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[121]. NAFLD patients with advanced hepatic fibrosis
have shown a reduction in circulatory adiponectin levels
[122, 123]. Additionally, decreased serum adiponectin
levels are inversely correlated with insulin resistance in
patients with NAFLD [124]. Contrary to these findings,
other studies in humans showed that increased serum
adiponectin levels are positively correlated with cirrhosis
[125]. Elevated serum adiponectin levels are considered
as a biomarker of renal dysfunction [126], impaired renal
metabolic environment [127] and end-stage renal disease
[128] in patients with CKD.
It is well-researched that pharmacological elevation
of circulatory adiponectin levels can ameliorate obesity-related MetS. Studies in both animals and humans
showed that using PPARγ agonist including thiazolidinediones (TZD), a diabetic medication, can increase
the levels of circulatory adiponectin [129, 130]. Medicinal plant-derived natural compounds such as astragaloside II and isoastragaloside I were shown to alleviate
hyperglycemia as well as improve glucose tolerance and
insulin sensitivity through increasing the production of
adiponectin in obese mice [131]. Extract from Zataria
multiflora, a plant of the Lamiaceae family, is shown to
increase PPARγ-mediated circulatory adiponectin levels
and subsequent improvement of insulin sensitivity and
reduced glucose levels in insulin-resistant rats [132]. A
dietary supplement such as vitamin E increases plasma
adiponectin mRNA expression and protein levels in
mice through the activation of PPARγ signaling [133].
Additionally, adiponectin mRNA expression and protein secretion were elevated in 3T3-L1 cells after vitamin
E treatment [133]. Treatment with Wy-14643, a PPARα
agonist is shown to increase the mRNA expression of
AdipoR1 and AdipoR2 in epididymal white adipose tissue (EWAT) of obese diabetic mice [134]. Treatment
with Rosiglitazone increased the mRNA expression of
AdipoR1 and AdipoR2 in isolated ventricular myocytes
from rats [50]. Expression of AdipoR1 and AdipoR2
mRNAs also increased in Pioglitazone treated human
skeletal muscle [135]. Administration of telmisartan, an
angiotensin receptor blocker, is shown to upregulate the
expression of myocardial adiponectin and AdipoR2 as
well as abdominal aortic AdipoR1 in diabetic rats [136].
The administration of metformin, a well-established diabetic drug, is associated with the upregulation of AdipoR1 and AdipoR2 in skeletal muscle and AdipoR1 in rat
EWAT [137].

Concluding remarks and future directions
Nowadays the molecular insights of adipocyte biology and associated adipokines are gaining more attention towards the discovery of novel therapeutics for
treating MetS and associated complications. Among
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Fig. 8 Tissue-specific role of adiponectin

all the adipokines characterized so far, adiponectin got
more attention due to its pleiotropic role over the other
adipokines. A vast majority of adiponectin research
in humans and animals studied only the correlation
between different diseased states and circulatory adiponectin levels. However, the tissue-specific expression,
as well as the cell signaling mechanism of adiponectin,
are not well characterized so far. More research needs to
be carried out in animal and human models to establish
tissue-specific precise mechanisms of adiponectin in different diseased conditions.
Circulatory adiponectin plays important roles as a biomarker in MetS and associated CVDs and has cardioprotective, insulin-sensitizing and direct beneficial metabolic
effects. Therefore, pharmacological or genetic interventions can be used to increase the levels of systemic adiponectin in MetS and associated CVDs. Additionally,
adiponectin-induced activation of AdipoR1/AdipoR2
is associated with multiple signaling pathways in a wide
range of cell types including skeletal muscle cells, cardiomyocytes, vascular ECs, VSMCs, hepatocytes, pancreatic
β-cells and BMSCs (Fig. 8). Discovering potential therapeutics that can modulate the tissue-specific expression/
activation of adiponectin and its receptors AdipoR1/AdipoR2 can pave the way to treat tissue-specific effects of
MetS.
Most of the pharmacological approaches studied so far
used to enhance the levels of circulatory adiponectin as
well as PPARα/PPARγ-mediated increase in AdipoR1/

AdipoR2 expression in humans and rodents. However,
there are several downstream targets of adiponectin
signaling including AMPK, mTOR, PGC1α, RhoA and
SMADs in different tissue types (Figs. 1, 2, 3, 4, 5, 6, and
7) that can be used as therapeutic targets to modulate
the tissue-specific activities of adiponectin in different
pathological conditions. Caloric restriction and exercise
training have already been proven as effective lifestyle
interventions to elevate systemic adiponectin levels in
patients with MetS. Therefore, simultaneous use of pharmacological and lifestyle interventions can potentiate the
elevation of circulatory adiponectin levels in MetS.
Authors’ contributions
BR: Drafted the manuscript and made the figures. SSP: Supervised, reviewed
and edited the manuscript. Both authors read and approved the final
manuscript.
Funding
SSP was partially supported by NHLBI-NIH grant 1R01HL139877-01A1 and an
internal grant from Henry Ford Health System A10249 and BR was supported
by Discretionary Fellowship of Department of Physiology and Thomas C.
Rumble University Graduate Fellowship from Wayne State University.
Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
All authors have their consent to participate.

Roy and Palaniyandi Cell Biosci

(2021) 11:77

Competing interests
The authors declare that they have no competing interests.
Author details
1
Division of Hypertension and Vascular Research, Department of Internal
Medicine, Henry Ford Health System, Integrative Biosciences Center (IBio),
Room #3402, 6135 Woodward, Detroit, MI 48202, USA. 2 Department of Physiology, Wayne State University, Detroit, MI 48202, USA.
Received: 25 February 2021 Accepted: 7 April 2021

References
1. Nolan PB, et al. Prevalence of metabolic syndrome and metabolic syndrome components in young adults: a pooled analysis. Prev Med Rep.
2017;7:211–5.
2. Wilson PW, et al. Metabolic syndrome as a precursor of cardiovascular
disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–72.
3. Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. 2020;21(4):1219.
4. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target
tissues. J Mol Cell Biol. 2016;8(2):101–9.
5. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321.
6. Krause MP, Milne KJ, Hawke TJ. Adiponectin-consideration for its role in
skeletal muscle health. Int J Mol Sci. 2019;20(7):1528.
7. Schindler M, et al. Adiponectin stimulates lipid metabolism via AMPK in
rabbit blastocysts. Hum Reprod. 2017;32(7):1382–92.
8. Argiles JM, et al. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc.
2016;17(9):789–96.
9. Tyrovolas S, et al. Skeletal muscle mass in relation to 10 year cardiovascular disease incidence among middle aged and older adults: the
ATTICA study. J Epidemiol Community Health. 2020;74(1):26–31.
10. Shishikura K, et al. Association between skeletal muscle mass and
insulin secretion in patients with type 2 diabetes mellitus. Endocr J.
2014;61(3):281–7.
11. Martinez-Huenchullan SF, et al. Skeletal muscle adiponectin induction
in obesity and exercise. Metabolism. 2020;102:154008.
12. Tanaka Y, et al. Adiponectin promotes muscle regeneration through
binding to T-cadherin. Sci Rep. 2019;9(1):16.
13. Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol.
2016;8(2):93–100.
14. Henstridge DC, Febbraio MA. Adiponectin sparks an interest in calcium.
Cell Metab. 2010;11(6):447–9.
15. Yoon MJ, et al. Adiponectin increases fatty acid oxidation in skeletal
muscle cells by sequential activation of AMP-activated protein kinase,
p38 mitogen-activated protein kinase, and peroxisome proliferatoractivated receptor alpha. Diabetes. 2006;55(9):2562–70.
16. Keshvari S, et al. Muscle-specific overexpression of AdipoR1 or AdipoR2
gives rise to common and discrete local effects whilst AdipoR2 promotes additional systemic effects. Sci Rep. 2017;7:41792.
17. Ito R, et al. Activation of adiponectin receptors has negative impact on
muscle mass in C2C12 myotubes and fast-type mouse skeletal muscle.
PLoS ONE. 2018;13(10):e0205645.
18. Nicholson T, et al. The role of adipokines in skeletal muscle inflammation and insulin sensitivity. J Inflamm. 2018;15:9.
19. Safwat Y, et al. Modulation of skeletal muscle performance and SERCA
by exercise and adiponectin gene therapy in insulin-resistant rat. DNA
Cell Biol. 2013;32(7):378–85.
20. Abou-Samra M, et al. Adiponectin and its mimics on skeletal muscle:
insulin sensitizers, fat burners, exercise mimickers, muscling pills … or
everything together? Int J Mol Sci. 2020;21(7):2620.
21. Dionyssiotis Y. Sarcopenia in the elderly. Eur Endocrinol.
2019;15(1):13–4.
22. Bauer J, et al. Sarcopenia: a time for action. An SCWD position paper. J
Cachexia Sarcopenia Muscle. 2019;10(5):956–61.

Page 16 of 18

23. Adachi H, et al. Long-term retrospective observation study to evaluate
effects of adiponectin on skeletal muscle in renal transplant recipients.
Sci Rep. 2020;10(1):10723.
24. Li CW, et al. Circulating factors associated with sarcopenia during
ageing and after intensive lifestyle intervention. J Cachexia Sarcopenia
Muscle. 2019;10(3):586–600.
25. Sawaguchi T, et al. Association of serum leptin and adiponectin concentrations with echocardiographic parameters and pathophysiological states in patients with cardiovascular disease receiving cardiovascular surgery. PLoS ONE. 2019;14(11):e0225008.
26. Nakatsuji H, et al. Correlation of insulin resistance and motor function in
spinal and bulbar muscular atrophy. J Neurol. 2017;264(5):839–47.
27. Civitarese AE, et al. Role of adiponectin in human skeletal muscle
bioenergetics. Cell Metab. 2006;4(1):75–87.
28. Ryu J, et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. 2014;7(4):1227–38.
29. Kitada M, et al. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Front Endocrinol. 2019;10:187.
30. Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature.
2010;464(7293):1313–9.
31. Ge Y, Yoon MS, Chen J. Raptor and Rheb negatively regulate skeletal
myogenesis through suppression of insulin receptor substrate 1 (IRS1).
J Biol Chem. 2011;286(41):35675–82.
32. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond.
Am J Physiol Endocrinol Metab. 2009;296(1):E22-36.
33. Jaminon A, et al. The role of vascular smooth muscle cells in arterial
remodeling: focus on calcification-related processes. Int J Mol Sci.
2019;20(22):5694.
34. Lovren F, et al. Adiponectin primes human monocytes into alternative
anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol.
2010;299(3):H656–63.
35. Guo R, et al. Adiponectin and its receptors are involved in hypertensive
vascular injury. Mol Med Rep. 2018;17(1):209–15.
36. Ding M, et al. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex
1 and FoxO4. Arterioscler Thromb Vasc Biol. 2011;31(6):1403–10.
37. Ding M, et al. Vascular smooth muscle cell-derived adiponectin:
a paracrine regulator of contractile phenotype. J Mol Cell Cardiol.
2012;52(2):474–84.
38. Zhang W, et al. Adiponectin affects vascular smooth muscle cell
proliferation and apoptosis through modulation of the mitofusin2-mediated Ras-Raf-Erk1/2 signaling pathway. Mol Med Rep.
2015;12(3):4703–7.
39. Nour-Eldine W, et al. Adiponectin attenuates angiotensin II-induced
vascular smooth muscle cell remodeling through nitric oxide and the
RhoA/ROCK pathway. Front Pharmacol. 2016;7:86.
40. Woodcock EA, Matkovich SJ. Cardiomyocytes structure, function and
associated pathologies. Int J Biochem Cell Biol. 2005;37(9):1746–51.
41. Mouton AJ, et al. Obesity, hypertension, and cardiac dysfunction: novel
roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789–806.
42. Gariballa S, et al. Total adiponectin in overweight and obese subjects
and its response to visceral fat loss. BMC Endocr Disord. 2019;19(1):55.
43. Aleidi S, et al. Adiponectin serum levels correlate with insulin resistance
in type 2 diabetic patients. Saudi Pharm J. 2015;23(3):250–6.
44. Kim DH, et al. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32.
45. Kou H, et al. Relationship among adiponectin, insulin resistance and
atherosclerosis in non-diabetic hypertensive patients and healthy
adults. Clin Exp Hypertens. 2018;40(7):656–63.
46. Springer J, Anker SD, Doehner W. Adiponectin resistance in heart failure
and the emerging pattern of metabolic failure in chronic heart failure.
Circ Heart Fail. 2010;3(2):181–2.
47. Lindberg S, et al. Low adiponectin levels and increased risk of type
2 diabetes in patients with myocardial infarction. Diabetes Care.
2014;37(11):3003–8.
48. Pineiro R, et al. Adiponectin is synthesized and secreted by human and
murine cardiomyocytes. FEBS Lett. 2005;579(23):5163–9.
49. Nanayakkara G, et al. The cardio-protective signaling and mechanisms
of adiponectin. Am J Cardiovasc Dis. 2012;2(4):253–66.

Roy and Palaniyandi Cell Biosci

(2021) 11:77

50. Ding G, et al. Adiponectin and its receptors are expressed in adult
ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol.
2007;43(1):73–84.
51. Dong F, Ren J. Adiponectin improves cardiomyocyte contractile function in db/db diabetic obese mice. Obesity. 2009;17(2):262–8.
52. Cao T, et al. AdipoR1/APPL1 potentiates the protective effects of
globular adiponectin on angiotensin II-induced cardiac hypertrophy
and fibrosis in neonatal rat atrial myocytes and fibroblasts. PLoS ONE.
2014;9(8):e103793.
53. Niemann B, et al. CTRP9 mediates protective effects in cardiomyocytes
via AMPK- and adiponectin receptor-mediated induction of antioxidant response. Cells. 2020;9(5):1229.
54. Amin RH, et al. Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine
mechanism. Am J Physiol Heart Circ Physiol. 2010;299(3):H690–8.
55. Lei X, et al. Exenatide reduces cardiomyocyte apoptosis by stimulating
adiponectin secretion and activating APPL1-AMPK-PPARalpha axis. Ann
Transl Med. 2019;7(14):326.
56. Li Y, et al. Adiponectin upregulates MiR-133a in cardiac hypertrophy
through AMPK activation and reduced ERK1/2 phosphorylation. PLoS
ONE. 2016;11(2):e0148482.
57. Palanivel R, et al. Adiponectin stimulates Rho-mediated actin cytoskeleton remodeling and glucose uptake via APPL1 in primary cardiomyocytes. Metabolism. 2014;63(10):1363–73.
58. Fang X, et al. An APPL1-AMPK signaling axis mediates beneficial
metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol
Metab. 2010;299(5):E721–9.
59. Potenza MA, et al. Activation of AMPK/SIRT1 axis is required for
adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats. PLoS ONE. 2019;14(1):e0210654.
60. Holland WL, et al. Receptor-mediated activation of ceramidase
activity initiates the pleiotropic actions of adiponectin. Nat Med.
2011;17(1):55–63.
61. Zhu Q, et al. Adiponectin facilitates postconditioning cardioprotection
through both AMPK-dependent nuclear and AMPK-independent mitochondrial STAT3 activation. Oxid Med Cell Longev. 2020;2020:4253457.
62. Tao L, et al. Adiponectin cardioprotection after myocardial ischemia/
reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115(11):1408–16.
63. Cai X, et al. Adiponectin reduces carotid atherosclerotic plaque formation in ApoE−/− mice: roles of oxidative and nitrosative stress and
inducible nitric oxide synthase. Mol Med Rep. 2015;11(3):1715–21.
64. Maruyama S, et al. Adiponectin ameliorates doxorubicin-induced
cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem.
2011;286(37):32790–800.
65. Shibata R, et al. Adiponectin protects against myocardial ischemiareperfusion injury through AMPK- and COX-2-dependent mechanisms.
Nat Med. 2005;11(10):1096–103.
66. Ikeda Y, et al. Cyclooxygenase-2 induction by adiponectin is regulated
by a sphingosine kinase-1 dependent mechanism in cardiac myocytes.
FEBS Lett. 2008;582(7):1147–50.
67. Rajendran P, et al. The vascular endothelium and human diseases. Int J
Biol Sci. 2013;9(10):1057–69.
68. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium:
pathophysiological basis and clinical perspectives. Physiol Rev.
2011;91(1):327–87.
69. Heiss EH, Dirsch VM. Regulation of eNOS enzyme activity by posttranslational modification. Curr Pharm Des. 2014;20(22):3503–13.
70. Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15(5):292–316.
71. Chen Z, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res.
2009;104(4):496–505.
72. Cheng KK, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1
in endothelial cells. Diabetes. 2007;56(5):1387–94.
73. Amour J, et al. Role of heat shock protein 90 and endothelial nitric
oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology. 2009;110(2):317–25.

Page 17 of 18

74. Xi W, et al. Stimulated HSP90 binding to eNOS and activation of the
PI3-Akt pathway contribute to globular adiponectin-induced NO
production: vasorelaxation in response to globular adiponectin.
Biochem Biophys Res Commun. 2005;332(1):200–5.
75. Kim JE, et al. Adiponectin inhibits palmitate-induced apoptosis
through suppression of reactive oxygen species in endothelial cells:
involvement of cAMP/protein kinase A and AMP-activated protein
kinase. J Endocrinol. 2010;207(1):35–44.
76. Liu T, et al. NF-kappaB signaling in inflammation. Signal Transduct
Target Ther. 2017;2:1–9.
77. Wang X, et al. Adiponectin improves NF-kappaB-mediated inflammation and abates atherosclerosis progression in apolipoprotein
E-deficient mice. Lipids Health Dis. 2016;15:33.
78. Adya R, et al. Protective actions of globular and full-length adiponectin on human endothelial cells: novel insights into adiponectininduced angiogenesis. J Vasc Res. 2012;49(6):534–43.
79. Shah D, Torres C, Bhandari V. Adiponectin deficiency induces
mitochondrial dysfunction and promotes endothelial activation and
pulmonary vascular injury. FASEB J. 2019;33(12):13617–31.
80. Zhou Z, Xu MJ, Gao B. Hepatocytes: a key cell type for innate immunity. Cell Mol Immunol. 2016;13(3):301–15.
81. Gamberi T, et al. Adiponectin signaling pathways in liver diseases.
Biomedicines. 2018;6(2):52.
82. Combs TP, Marliss EB. Adiponectin signaling in the liver. Rev Endocr
Metab Disord. 2014;15(2):137–47.
83. Foretz M, Viollet B. Regulation of hepatic metabolism by AMPK. J
Hepatol. 2011;54(4):827–9.
84. Zhang X, et al. Unraveling the regulation of hepatic gluconeogenesis.
Front Endocrinol. 2018;9:802.
85. Lee JM, et al. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor
small heterodimer partner. J Biol Chem. 2010;285(42):32182–91.
86. Berasi SP, et al. Inhibition of gluconeogenesis through transcriptional
activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem.
2006;281(37):27167–77.
87. Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding
proteins—recent advances in elucidating adiponectin signalling
pathways. FEBS Lett. 2010;584(20):4280–6.
88. Awazawa M, et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem
Biophys Res Commun. 2009;382(1):51–6.
89. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty
acids in the maintenance of metabolic homeostasis through adipose
tissue crosstalk. Cell Metab. 2016;23(5):770–84.
90. Miller RA, et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J
Clin Invest. 2011;121(6):2518–28.
91. Holland WL, et al. Inducible overexpression of adiponectin receptors
highlight the roles of adiponectin-induced ceramidase signaling in
lipid and glucose homeostasis. Mol Metab. 2017;6(3):267–75.
92. Holland WL, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab.
2013;17(5):790–7.
93. Zhou M, et al. Mitochondrial dysfunction contributes to the increased
vulnerabilities of adiponectin knockout mice to liver injury. Hepatology.
2008;48(4):1087–96.
94. Masaki T, et al. Adiponectin protects LPS-induced liver injury
through modulation of TNF-alpha in KK-Ay obese mice. Hepatology.
2004;40(1):177–84.
95. Haukeland JW, et al. Systemic inflammation in nonalcoholic fatty
liver disease is characterized by elevated levels of CCL2. J Hepatol.
2006;44(6):1167–74.
96. Finelli C, Tarantino G. What is the role of adiponectin in obesity
related non-alcoholic fatty liver disease? World J Gastroenterol.
2013;19(6):802–12.
97. Rorsman P, Ashcroft FM. Pancreatic beta-cell electrical activity and
insulin secretion: of mice and men. Physiol Rev. 2018;98(1):117–214.
98. Kharroubi I, et al. Expression of adiponectin receptors in pancreatic beta
cells. Biochem Biophys Res Commun. 2003;312(4):1118–22.
99. Lee YH, et al. Effects of leptin and adiponectin on pancreatic beta-cell
function. Metabolism. 2011;60(12):1664–72.

Roy and Palaniyandi Cell Biosci

(2021) 11:77

100. Wijesekara N, et al. Adiponectin-induced ERK and Akt phosphorylation
protects against pancreatic beta cell apoptosis and increases insulin
gene expression and secretion. J Biol Chem. 2010;285(44):33623–31.
101. Okamoto M, et al. Adiponectin induces insulin secretion in vitro and
in vivo at a low glucose concentration. Diabetologia. 2008;51(5):827–35.
102. Mahmoodzadeh Sagheb M, et al. The effects of leptin and adiponectin
on Pdx1, Foxm1, and PPARgamma transcription in rat islets of langerhans. Hepat Mon. 2013;13(6):e9055.
103. Ye R, et al. Adiponectin-mediated antilipotoxic effects in regenerating
pancreatic islets. Endocrinology. 2015;156(6):2019–28.
104. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin
sensitivity? Mol Metab. 2013;2(3):133–41.
105. Ye R, et al. Adiponectin is essential for lipid homeostasis and survival
under insulin deficiency and promotes beta-cell regeneration. Elife.
2014;3:e03851.
106. Winzell MS, et al. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun.
2004;321(1):154–60.
107. Roy B, et al. Molecular mechanisms of obesity-induced osteoporosis
and muscle atrophy. Front Physiol. 2016;7:439.
108. Basurto L, et al. Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol. 2009;160(2):289–93.
109. Jiang X, et al. Effect of intermittent administration of adiponectin on
bone regeneration following mandibular osteodistraction in rabbits. J
Orthop Res. 2011;29(7):1081–5.
110. Oshima K, et al. Adiponectin increases bone mass by suppressing
osteoclast and activating osteoblast. Biochem Biophys Res Commun.
2005;331(2):520–6.
111. Wu Y, et al. Central adiponectin administration reveals new regulatory
mechanisms of bone metabolism in mice. Am J Physiol Endocrinol
Metab. 2014;306(12):E1418–30.
112. Luo E, et al. Sustained release of adiponectin improves osteogenesis
around hydroxyapatite implants by suppressing osteoclast activity in
ovariectomized rabbits. Acta Biomater. 2012;8(2):734–43.
113. Wang Y, et al. Adiponectin regulates BMSC osteogenic differentiation
and osteogenesis through the Wnt/beta-catenin pathway. Sci Rep.
2017;7(1):3652.
114. Huang CY, et al. Adiponectin increases BMP-2 expression in
osteoblasts via AdipoR receptor signaling pathway. J Cell Physiol.
2010;224(2):475–83.
115. Lee HW, et al. Adiponectin stimulates osteoblast differentiation through
induction of COX2 in mesenchymal progenitor cells. Stem Cells.
2009;27(9):2254–62.
116. Yu L, et al. Adiponectin regulates bone marrow mesenchymal stem cell
niche through a unique signal transduction pathway: an approach for
treating bone disease in diabetes. Stem Cells. 2015;33(1):240–52.
117. Liu Y, Vu V, Sweeney G. Examining the potential of developing and
implementing use of adiponectin-targeted therapeutics for metabolic
and cardiovascular diseases. Front Endocrinol. 2019;10:842.
118. Lindberg S, et al. Adiponectin, type 2 diabetes and cardiovascular risk.
Eur J Prev Cardiol. 2015;22(3):276–83.
119. Kojima S, et al. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked
reductions of adiponectin in women after acute myocardial infarction.
Atherosclerosis. 2007;194(1):204–13.
120. Lindberg S, et al. Cardio-adipose tissue cross-talk: relationship between
adiponectin, plasma pro brain natriuretic peptide and incident heart
failure. Eur J Heart Fail. 2014;16(6):633–8.
121. Wang Z, et al. The association between serum adiponectin and
3-month outcome after ischemic stroke. Cardiovasc Diabetol.
2019;18(1):105.

Page 18 of 18

122. Savvidou S, et al. Low serum adiponectin levels are predictive of
advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol.
2009;43(8):765–72.
123. Bugianesi E, et al. Plasma adiponectin in nonalcoholic fatty liver is
related to hepatic insulin resistance and hepatic fat content, not to liver
disease severity. J Clin Endocrinol Metab. 2005;90(6):3498–504.
124. Gad H. Study of plasma adiponectin and insulin resistance in subjects
with non-alcoholic fatty liver disease. Arch Gen Intern Med. 2018;2(3):4.
125. da Silva TE, et al. Clinical significance of serum adiponectin and resistin
levels in liver cirrhosis. Ann Hepatol. 2018;17(2):286–99.
126. Song SH, et al. High serum adiponectin as a biomarker of renal dysfunction: results from the KNOW-CKD study. Sci Rep. 2020;10(1):5598.
127. Guebre-Egziabher F, et al. Adiponectin in chronic kidney disease is
related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005;20(1):129–34.
128. Kuo IC, et al. The association of adiponectin with metabolic syndrome
and clinical outcome in patients with non-diabetic chronic kidney
disease. PLoS ONE. 2019;14(7):e0220158.
129. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab.
2012;23(5):205–15.
130. Werner C, et al. The peroxisome proliferator-activated receptor-gamma
agonist pioglitazone increases number and function of endothelial
progenitor cells in patients with coronary artery disease and normal
glucose tolerance. Diabetes. 2007;56(10):2609–15.
131. Xu A, et al. Selective elevation of adiponectin production by the
natural compounds derived from a medicinal herb alleviates insulin
resistance and glucose intolerance in obese mice. Endocrinology.
2009;150(2):625–33.
132. Mohammadi A, Gholamhoseinian A, Fallah H. Zataria multiflora
increases insulin sensitivity and PPARgamma gene expression
in high fructose fed insulin resistant rats. Iran J Basic Med Sci.
2014;17(4):263–70.
133. Landrier JF, et al. Adiponectin expression is induced by vitamin E via a
peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology. 2009;150(12):5318–25.
134. Tsuchida A, et al. Peroxisome proliferator-activated receptor (PPAR)
alpha activation increases adiponectin receptors and reduces
obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes.
2005;54(12):3358–70.
135. Coletta DK, et al. Pioglitazone stimulates AMP-activated protein kinase
signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia. 2009;52(4):723–32.
136. Guo Z, et al. Effect of telmisartan on the expression of adiponectin
receptors and nicotinamide adenine dinucleotide phosphate oxidase
in the heart and aorta in type 2 diabetic rats. Cardiovasc Diabetol.
2012;11:94.
137. Metais C, et al. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism.
2008;57(7):946–53.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

